CN1853730A - 用于治疗癌症的修饰细胞因子 - Google Patents
用于治疗癌症的修饰细胞因子 Download PDFInfo
- Publication number
- CN1853730A CN1853730A CNA2006100092723A CN200610009272A CN1853730A CN 1853730 A CN1853730 A CN 1853730A CN A2006100092723 A CNA2006100092723 A CN A2006100092723A CN 200610009272 A CN200610009272 A CN 200610009272A CN 1853730 A CN1853730 A CN 1853730A
- Authority
- CN
- China
- Prior art keywords
- tnf
- ngr
- tumor
- cytokine
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/65—Collagen; Gelatin; Keratin; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/525—Tumour necrosis factor [TNF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/57—IFN-gamma
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0819—Tripeptides with the first amino acid being acidic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1021—Tetrapeptides with the first amino acid being acidic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L89/00—Compositions of proteins; Compositions of derivatives thereof
- C08L89/04—Products derived from waste materials, e.g. horn, hoof or hair
- C08L89/06—Products derived from waste materials, e.g. horn, hoof or hair derived from leather or skin, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/41—Particular ingredients further characterized by their size
- A61K2800/412—Microsized, i.e. having sizes between 0.1 and 100 microns
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Dermatology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Diabetes (AREA)
- Polymers & Plastics (AREA)
- Birds (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
Abstract
Description
治疗 | 动物(数量) | 剂量(μg) | 治疗后存活率(%)a) | |||||||
第3天 | 第7天 | 第14天 | 第21天 | 第30天 | 第38天(2ndch)b) | 第62天(3o ch)b) | 第92天 | |||
无TNFNGR-TNF | 184991499101091399 | 013927541081392754108 | 100100100100100550100100100100330 | 020555557557080888533 | 0022140102055300 | 11710202223 | 0010201115 | 001115 | 1115 | 1115 |
竞争剂 | WM15与肿瘤相关血管的结合 |
无NGR-TNF(25μg/ml)NGR-IFNγ(50μg/ml)CNGRC(100μg/ml)TNF(25μg/ml)人血清白蛋白(25μg/ml)合成CgA(60-68)(100μg/ml) | +---+++ |
Claims (16)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ITMI2000A000249 | 2000-02-15 | ||
IT2000MI000249A IT1317835B1 (it) | 2000-02-15 | 2000-02-15 | Citochine modificate per uso nella terapia del cancro. |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN018077129A Division CN1446261B (zh) | 2000-02-15 | 2001-02-13 | 用于治疗癌症的修饰细胞因子 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1853730A true CN1853730A (zh) | 2006-11-01 |
CN1853730B CN1853730B (zh) | 2013-07-24 |
Family
ID=11444017
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN018077129A Expired - Fee Related CN1446261B (zh) | 2000-02-15 | 2001-02-13 | 用于治疗癌症的修饰细胞因子 |
CN2006100092723A Expired - Fee Related CN1853730B (zh) | 2000-02-15 | 2001-02-13 | 用于治疗癌症的修饰细胞因子 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN018077129A Expired - Fee Related CN1446261B (zh) | 2000-02-15 | 2001-02-13 | 用于治疗癌症的修饰细胞因子 |
Country Status (29)
Country | Link |
---|---|
US (4) | US7150869B2 (zh) |
EP (2) | EP2080804A1 (zh) |
JP (1) | JP4836384B2 (zh) |
KR (1) | KR100888761B1 (zh) |
CN (2) | CN1446261B (zh) |
AT (1) | ATE424461T1 (zh) |
AU (1) | AU784173C (zh) |
BG (1) | BG65931B1 (zh) |
BR (1) | BR0108391A (zh) |
CA (1) | CA2399986C (zh) |
CY (1) | CY1109034T1 (zh) |
CZ (1) | CZ299486B6 (zh) |
DE (1) | DE60137835D1 (zh) |
DK (1) | DK1255845T3 (zh) |
EA (1) | EA007838B1 (zh) |
ES (1) | ES2322234T3 (zh) |
HK (1) | HK1048649B (zh) |
HU (1) | HU227894B1 (zh) |
IL (2) | IL150984A0 (zh) |
IT (1) | IT1317835B1 (zh) |
MX (1) | MXPA02007899A (zh) |
NO (1) | NO330913B1 (zh) |
PL (1) | PL207263B1 (zh) |
PT (1) | PT1255845E (zh) |
SI (1) | SI1255845T1 (zh) |
SK (1) | SK287550B6 (zh) |
UA (1) | UA85365C2 (zh) |
WO (1) | WO2001061017A2 (zh) |
ZA (1) | ZA200206450B (zh) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7309694B2 (en) | 2000-02-15 | 2007-12-18 | Fondazione Centro San Raffaele Del Monte Tabor | Modified cytokines for use in cancer therapy |
IT1317835B1 (it) | 2000-02-15 | 2003-07-15 | San Raffaele Centro Fond | Citochine modificate per uso nella terapia del cancro. |
US7109303B2 (en) * | 2000-02-15 | 2006-09-19 | Fondazione Centro San Raffaele Del Monte Tabor | Modified cytokines for use in cancer therapy |
ES2269361T3 (es) * | 2000-02-24 | 2007-04-01 | Philogen S.P.A. | Composiciones y metodos para tratamiento de la angiogenesis en lesiones patologicas. |
AU2006200762B2 (en) * | 2000-02-24 | 2008-08-21 | Philogen S.R.L. | Compositions and methods for treatment of angiogenesis in pathological lesions |
DK1471974T3 (da) | 2002-02-06 | 2007-12-03 | Ares Trading Sa | Tumornekrose-faktor kombineret med interferon ved demyeliniserende sygdomme |
EP1346729A1 (en) * | 2002-03-19 | 2003-09-24 | Cardiovascular Research Institute Maastricht | Targeting of myocardial angiogenesis through CD13/APN |
GB0209893D0 (en) * | 2002-04-30 | 2002-06-05 | Molmed Spa | Conjugate |
GB0209896D0 (en) * | 2002-04-30 | 2002-06-05 | Molmed Spa | Conjugate |
EP1613344A2 (en) * | 2003-03-31 | 2006-01-11 | Greenville Hospital System | Anti-tumor vasculature effects of human serum albumin derivatives |
GB0312309D0 (en) * | 2003-05-29 | 2003-07-02 | Gaslini Children S Hospital G | Targeted liposome |
EP1831254B1 (en) | 2004-12-23 | 2012-06-06 | Molmed SpA | Conjugation product |
US7625555B2 (en) * | 2007-06-18 | 2009-12-01 | Novagen Holding Corporation | Recombinant human interferon-like proteins |
GB0803076D0 (en) * | 2008-02-20 | 2008-03-26 | Univ Ghent | Mucosal Membrane Receptor and uses thereof |
JP5559772B2 (ja) * | 2008-05-13 | 2014-07-23 | モルメド エスピーエー | 中皮腫の治療のためのコンジュゲート |
CN108314741B (zh) * | 2018-03-22 | 2021-08-03 | 中国人民解放军第四军医大学 | 一种肿瘤血管靶向抗癌肽nkl-dota及其制备方法 |
EP3882257A1 (en) | 2020-03-20 | 2021-09-22 | Ospedale San Raffaele S.r.l. | Ngr conjugates and uses thereof |
WO2023170209A1 (en) | 2022-03-09 | 2023-09-14 | Ospedale San Raffaele Srl | Fusion proteins and uses thereof |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3423234A1 (de) * | 1984-06-23 | 1986-02-06 | Boehringer Ingelheim International GmbH, 6507 Ingelheim | Synergistische mischungen von interferonen und tumor-nekrose-faktor |
US4650674A (en) * | 1984-07-05 | 1987-03-17 | Genentech, Inc. | Synergistic cytotoxic composition |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
US4863713A (en) | 1986-06-23 | 1989-09-05 | The Board Of Trustees Of Leland Stanford Jr. Univ. | Method and system for administering therapeutic and diagnostic agents |
US5214131A (en) * | 1988-05-06 | 1993-05-25 | Sumitomo Pharmaceuticals Company, Limited | Polyethylene glycol derivatives, modified peptides and production thereof |
US5091176A (en) * | 1988-11-02 | 1992-02-25 | W. R. Grace & Co.-Conn. | Polymer-modified peptide drugs having enhanced biological and pharmacological activities |
JPH04218000A (ja) * | 1990-02-13 | 1992-08-07 | Kirin Amgen Inc | 修飾ポリペプチド |
IT1245748B (it) | 1990-12-21 | 1994-10-14 | Mini Ricerca Scient Tecnolog | Preparazione includente anticorpi monoclonali biotinilati, avidina e biotina, per la diagnosi di affezioni tumorali e suo impiego |
US5595732A (en) * | 1991-03-25 | 1997-01-21 | Hoffmann-La Roche Inc. | Polyethylene-protein conjugates |
US5811512A (en) * | 1991-08-22 | 1998-09-22 | The Trustees Of The University Of Pennsylvania | Non-peptide peptidomimetics and related cyclic hexapeptides |
US5258517A (en) * | 1992-08-06 | 1993-11-02 | Sepracor, Inc. | Method of preparing optically pure precursors of paroxetine |
CA2178476A1 (en) | 1993-12-07 | 1995-06-15 | Neorx Corporation | Pretargeting methods and compounds |
US5888814A (en) * | 1994-06-06 | 1999-03-30 | Chiron Corporation | Recombinant host cells encoding TNF proteins |
US5811388A (en) * | 1995-06-07 | 1998-09-22 | Cibus Pharmaceutical, Inc. | Delivery of drugs to the lower GI tract |
US5891418A (en) * | 1995-06-07 | 1999-04-06 | Rhomed Incorporated | Peptide-metal ion pharmaceutical constructs and applications |
JP2001501600A (ja) * | 1996-09-10 | 2001-02-06 | ザ バーナム インスティテュート | 腫瘍ホーミング分子、それに由来する結合体、およびその使用方法 |
US6576239B1 (en) * | 1996-09-10 | 2003-06-10 | The Burnham Institute | Angiogenic homing molecules and conjugates derived therefrom |
US6759509B1 (en) * | 1996-11-05 | 2004-07-06 | Bristol-Myers Squibb Company | Branched peptide linkers |
JP2001516055A (ja) * | 1997-09-10 | 2001-09-25 | ザ バーナム インスティチュート | 腫瘍中の血管形成血管系にホーミングする分子を同定する方法 |
US6180084B1 (en) * | 1998-08-25 | 2001-01-30 | The Burnham Institute | NGR receptor and methods of identifying tumor homing molecules that home to angiogenic vasculature using same |
IT1317835B1 (it) | 2000-02-15 | 2003-07-15 | San Raffaele Centro Fond | Citochine modificate per uso nella terapia del cancro. |
-
2000
- 2000-02-15 IT IT2000MI000249A patent/IT1317835B1/it active
-
2001
- 2001-02-13 MX MXPA02007899A patent/MXPA02007899A/es active IP Right Grant
- 2001-02-13 SI SI200130914T patent/SI1255845T1/sl unknown
- 2001-02-13 IL IL15098401A patent/IL150984A0/xx unknown
- 2001-02-13 AU AU44135/01A patent/AU784173C/en not_active Ceased
- 2001-02-13 AT AT01916988T patent/ATE424461T1/de active
- 2001-02-13 CZ CZ20023093A patent/CZ299486B6/cs not_active IP Right Cessation
- 2001-02-13 EP EP09001064A patent/EP2080804A1/en not_active Withdrawn
- 2001-02-13 SK SK1151-2002A patent/SK287550B6/sk not_active IP Right Cessation
- 2001-02-13 CN CN018077129A patent/CN1446261B/zh not_active Expired - Fee Related
- 2001-02-13 DK DK01916988T patent/DK1255845T3/da active
- 2001-02-13 PL PL362670A patent/PL207263B1/pl unknown
- 2001-02-13 CN CN2006100092723A patent/CN1853730B/zh not_active Expired - Fee Related
- 2001-02-13 BR BR0108391-0A patent/BR0108391A/pt active Search and Examination
- 2001-02-13 JP JP2001559854A patent/JP4836384B2/ja not_active Expired - Fee Related
- 2001-02-13 KR KR1020027010464A patent/KR100888761B1/ko not_active IP Right Cessation
- 2001-02-13 PT PT01916988T patent/PT1255845E/pt unknown
- 2001-02-13 WO PCT/EP2001/001543 patent/WO2001061017A2/en active IP Right Grant
- 2001-02-13 UA UA2002097447A patent/UA85365C2/ru unknown
- 2001-02-13 ES ES01916988T patent/ES2322234T3/es not_active Expired - Lifetime
- 2001-02-13 HU HU0300005A patent/HU227894B1/hu unknown
- 2001-02-13 EP EP01916988A patent/EP1255845B1/en not_active Expired - Lifetime
- 2001-02-13 EA EA200200808A patent/EA007838B1/ru not_active IP Right Cessation
- 2001-02-13 CA CA2399986A patent/CA2399986C/en not_active Expired - Fee Related
- 2001-02-13 DE DE60137835T patent/DE60137835D1/de not_active Expired - Lifetime
-
2002
- 2002-07-30 IL IL150984A patent/IL150984A/en not_active IP Right Cessation
- 2002-08-13 ZA ZA200206450A patent/ZA200206450B/en unknown
- 2002-08-13 NO NO20023833A patent/NO330913B1/no not_active IP Right Cessation
- 2002-08-14 BG BG106999A patent/BG65931B1/bg unknown
- 2002-08-15 US US10/218,906 patent/US7150869B2/en not_active Expired - Lifetime
-
2003
- 2003-01-21 HK HK03100495.7A patent/HK1048649B/zh not_active IP Right Cessation
-
2005
- 2005-06-27 US US11/166,099 patent/US7476721B2/en not_active Expired - Fee Related
-
2006
- 2006-10-25 US US11/585,934 patent/US7622556B2/en not_active Expired - Fee Related
-
2009
- 2009-05-06 CY CY20091100487T patent/CY1109034T1/el unknown
- 2009-10-27 US US12/606,937 patent/US20100196458A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1853730A (zh) | 用于治疗癌症的修饰细胞因子 | |
CN1264858C (zh) | 血管生成抑制三肽、组合物及其使用方法 | |
CN100340291C (zh) | F1t4(VEGFR-3)作为肿瘤显像和抗肿瘤治疗的靶 | |
EP1178826B1 (en) | Immunotherapy of b-cell malignancies using anti-cd22 antibodies | |
ES2241129T3 (es) | Inmunoterapia de malignidad de linfocitos b utilizando anticuerpos anti-cd22. | |
CN1333785A (zh) | 干扰素-β融合蛋白及用途 | |
CN1151170C (zh) | Mage肿瘤排斥抗原前体衍生的与hla-a2分子形成复合物的分离肽 | |
CN101076348A (zh) | 用于在受试者中诱导黑素原生成的组合物和方法 | |
CN1346279A (zh) | 联合应用抗血管生成和免疫治疗以治疗肿瘤和转移的方法 | |
CN1313895A (zh) | 蜂毒蛋白的有用特性和编码这种蜂毒蛋白的基因 | |
CN1309705A (zh) | Il-2选择性激动剂和拮抗剂 | |
CN1269832A (zh) | K-配体-新的免疫系统蛋白 | |
CN1173183A (zh) | 含有水溶性聚合物的bdnf与nt-3的结合物 | |
CN107213469A (zh) | 能够与配体偶联的单甲基缬氨酸化合物 | |
CN1313343A (zh) | N-端化学修饰的蛋白质组合物及方法 | |
CN1145077A (zh) | 免疫刺激单克隆抗体 | |
CN1194000A (zh) | 增强保护性免疫应答的方法 | |
AU2011200649A1 (en) | Methods for obtaining molecules with reduced immunogenicity | |
CN109414426A (zh) | 使用精氨酸耗竭剂的组合癌症免疫疗法 | |
EP3277313A1 (en) | Agents and compositions for eliciting an immune response | |
CN1129737A (zh) | 基因转移的修饰蛋白及其制备方法 | |
CN1511040A (zh) | 作为多种治疗模式基础的蛋白质的选择性剪接形式 | |
CN1735428A (zh) | 伴侣蛋白10的免疫抑制作用 | |
CN1533808A (zh) | 治疗冠状病毒感染和sars的组合物与方法 | |
CN1732016A (zh) | 用于癌症治疗的经修饰的细胞因子 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: SHENGLAI FALAI HOSPITAL CO., LTD. Free format text: FORMER OWNER: TABOR FUND CENTER Effective date: 20130819 |
|
C41 | Transfer of patent application or patent right or utility model | ||
C56 | Change in the name or address of the patentee |
Owner name: TABOR FUND CENTER Free format text: FORMER NAME: FONDAZIONE CENTRO SAN RAFFACLE DEL MONTE TABOR |
|
CP01 | Change in the name or title of a patent holder |
Address after: Milan Italy Patentee after: Tabor hills fund center Address before: Milan Italy Patentee before: San Rafael del Monte Tabo Fund Center |
|
TR01 | Transfer of patent right |
Effective date of registration: 20130819 Address after: Milan Italy Patentee after: San rafael hospital Co.,Ltd. Address before: Milan Italy Patentee before: Tabor hills fund center |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20130724 Termination date: 20190213 |
|
CF01 | Termination of patent right due to non-payment of annual fee |